Physician profile
Mark S Milner
NPI 1932171147
$1,217,462.95
in general payments reported to CMS, 2019-2025
33 companies · $302K in 2025
The $302K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183K · 2020: $167K · 2021: $153K · 2022: $91K · 2023: $99K · 2024: $222K · 2025: $302K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $248K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $162K · Consulting Fee: $147K · Travel and Lodging: $47K · Food and Beverage: $19K · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $247,925.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $161,640.00 |
| Consulting Fee | $146,876.25 |
| Travel and Lodging | $46,847.18 |
| Food and Beverage | $19,332.04 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $255,760.56 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $187,873.17 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Tarsus Pharmaceuticals, INC. | $145,469.20 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $114,142.22 | 2019-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $109,978.53 | 2019-2023 | Flarex |
| Oyster Point Pharma, INC. | $105,497.48 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $98,191.73 | 2019-2025 | |
| Alcon Vision LLC | $63,321.04 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Abbvie INC. | $39,340.41 | 2022-2025 | |
| Dompe US, INC. | $38,106.02 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $15,618.83 | 2019-2023 | |
| Shire North American Group INC | $15,104.16 | 2019 | |
| Alcon Research LLC | $13,000.00 | 2024-2025 | Tryptyr |
| Thea Pharma INC. | $7,403.38 | 2022-2024 | |
| Tearlab Corp | $2,169.18 | 2020-2023 | Tearlab Osmolarity System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,509.92 | 2020-2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,369.95 | 2019-2020 | |
| Glaukos Corporation | $1,050.74 | 2020-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Harrow Eye, LLC | $788.36 | 2023-2025 | Vevye, Iheezo, Triesence |
| Johnson & Johnson Surgical Vision, INC. | $597.01 | 2022-2025 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $319.03 | 2022-2025 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Ani Pharmaceuticals, INC. | $173.24 | 2024-2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $162.52 | 2019-2022 | |
| Sight Sciences, INC. | $161.51 | 2023-2024 | Omni Surgical System, Tearcare System |
| New World Medical,INC. | $77.36 | 2022-2023 | |
| Amgen INC. | $64.26 | 2024-2025 | Tepezza |
| Rxsight INC | $60.05 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $41.88 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $31.80 | 2021 | |
| Mallinckrodt Enterprises LLC | $25.53 | 2019 | |
| Omeros Corporation | $19.41 | 2021 | |
| Apellis Pharmaceuticals, INC. | $19.15 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $15.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$308,700.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Milner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.